Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Photo: Ritesh Uttamchandani/Hindustan Times via Getty Images
The Food and Drug Administration (FDA) on Thursday approved Aimovig, a new drug that would stop severe migraine headaches before they start.
By the numbers: The monthly self-injection treatment will cost $575 per month or $6,900 annually. Per the American Migraine Foundation, the neurological disease is the third most prevalent illness in the world, and over 36 million Americans suffer from migraines — more than those who have diabetes and asthma combined.